Diversity in Clinical Trials Improving, but We’re Not There Yet
Dr. Jean Bonnet, an advocate for diversity in clinical trials, says both sponsors and patients are to blame for the lack of diversity. He says grassroots communication is key to effecting change.
With Investors’ Eyes on Biotechs, Biotechs Must Be Transparent
With the government shutdown and public outcry over drug prices, biotech companies face new challenges when courting investors. That means transparency is more important than ever.